Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of antimicrobial agents 2020-08, Vol.56 (2), p.106052-106052, Article 106052
Hauptverfasser:	Hong, Sun In, Ryu, Byung-Han, Chong, Yong Pil, Lee, Seungjun, Kim, Sunjoo, Kim, Ho Cheol, Hong, Kyung-Wook, Bae, In-Gyu, Cho, Oh-Hyun
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvants, Immunologic - administration & dosage Adult Aged Antimalarials - administration & dosage Antiviral Agents - administration & dosage Betacoronavirus - growth & development Coronavirus Coronavirus Infections - drug therapy Coronavirus Infections - pathology COVID-19 Drug Therapy, Combination - methods Female Humans Hydroxychloroquine Hydroxychloroquine - administration & dosage Interferon Interferon beta-1b - administration & dosage Letter to the Editor Lopinavir - administration & dosage Lopinavir/ritonavir Male Middle Aged Pandemics Pneumonia - drug therapy Pneumonia, Viral - drug therapy Pneumonia, Viral - pathology Ritonavir - administration & dosage SARS-CoV-2 Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!